[ad_1]
Beyond spring (BYSI) said on Wednesday that a regimen containing its anti-cancer drug outperformed chemotherapy alone in lung cancer patients, and that BYSI action quadrupled pre-market to an all-time high before declining.
X
The company has tested a regimen containing its drug, plinabulin, against chemotherapy in patients with some form of lung cancer. The diet increased overall survival and improved other disease measures while avoiding a dangerous side effect associated with chemo.
Now BeyondSpring says it is preparing to seek approval for plinabulin in the United States and China. The results also paved the way for the use of plinabulin in combination with immuno-oncology drugs, thus expanding its potential use over time.
In morning stock exchange trading today, BYSI stock climbed 164.3%, trading near 25.50. At some point before market, stocks jumped 300% and jumped almost 200% once the regular session began. The shares closed below 10 Tuesday.
BYSI Stock Rockets on Cancer Test
BeyondSpring has studied a combination of plinabulin and chemotherapy as a second or third treatment option for patients with non-small cell lung cancer.
Compared with chemotherapy alone, the regimen increased overall survival at two and three years. It also improved the overall response rate and lengthened the time before patients’ disease got worse.
Notably, the diet significantly reduced incidents of severe neutropenia, a side effect of chemotherapy that increases a patient’s risk of infection. Diets containing docetaxel, the type of chemotherapy used in the study, had limited benefits due to severe neutropenia.
Plinabulin works by triggering the release of an immune defense protein called GEF-H1. BeyondSpring chief medical officer Dr Ramon Mohanlal said plinabulin could be added to checkpoint inhibitors, another class of cancer drugs.
“The mechanism of action of improving the immune system of plinabulin which is complementary to that of checkpoint inhibitors, and which justifies its combination in triple combination (immuno-oncology) in multiple tumor indications”, has t he declared in a written statement.
Stocks beat moving averages
The results sent BYSI stocks above their 50 and 200 day moving averages, according to MarketSmith.com.
Meanwhile, investment bank HC Wainwright raised BYSI stock from neutral to a buy note. The analyst has a target price of 100.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Amgen shares drop on lower forecast despite second quarter beat
Eli Lilly Stock hits record high as enthusiasm for Alzheimer’s disease grows
Find the best long-term investments with IBD’s long-term leaders
Receive timely buy and sell alerts with IBD ranking
Looking for the next apple or Amazon? Start With These S&P 500 Win Lists
[ad_2]
Source link